Monte Rosa Therapeutics, Inc. Banner Image

Monte Rosa Therapeutics, Inc.

  • Ticker GLUE
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Monte Rosa Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Boston, Massachusetts
Monte Rosa Therapeutics is a biotechnology company developing novel molecular glue degrader (MGD) medicines for patients living with serious diseases such as oncology, autoimmune and inflammatory diseases. The Company’s lead program, MRT-2359, is being developed in a Phase 1/2 study in MYC-driven tumors, including non-small cell lung cancer and small-cell lung cancer. MGDs are small moleculeMore protein degraders designed to employ the body’s natural mechanisms to eliminate therapeutically relevant proteins selectively. The Company’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) platform enables it to rapidly identify protein targets and design highly selective degraders by combining diverse libraries of proprietary MGDs with in-house proteomics, structural biology, A.I./machine learning, and computational chemistry capabilities.
Monte Rosa Therapeutics, Inc.

Most Recent Annual Report

Monte Rosa Therapeutics, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Monte Rosa Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!